CN111110677A - 用于治疗精神分裂症的组合物 - Google Patents

用于治疗精神分裂症的组合物 Download PDF

Info

Publication number
CN111110677A
CN111110677A CN202010012498.9A CN202010012498A CN111110677A CN 111110677 A CN111110677 A CN 111110677A CN 202010012498 A CN202010012498 A CN 202010012498A CN 111110677 A CN111110677 A CN 111110677A
Authority
CN
China
Prior art keywords
compound
formulation
pharmaceutical formulation
sleep
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010012498.9A
Other languages
English (en)
Chinese (zh)
Inventor
R.鲁斯林格
奥山昌弘
N.罗尔
S.瓦纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CN111110677A publication Critical patent/CN111110677A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202010012498.9A 2014-12-02 2015-11-30 用于治疗精神分裂症的组合物 Pending CN111110677A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462086691P 2014-12-02 2014-12-02
US62/086691 2014-12-02
US201562248071P 2015-10-29 2015-10-29
US62/248071 2015-10-29
CN201580065471.3A CN107567444A (zh) 2014-12-02 2015-11-30 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580065471.3A Division CN107567444A (zh) 2014-12-02 2015-11-30 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物

Publications (1)

Publication Number Publication Date
CN111110677A true CN111110677A (zh) 2020-05-08

Family

ID=54848909

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010012498.9A Pending CN111110677A (zh) 2014-12-02 2015-11-30 用于治疗精神分裂症的组合物
CN201580065471.3A Pending CN107567444A (zh) 2014-12-02 2015-11-30 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580065471.3A Pending CN107567444A (zh) 2014-12-02 2015-11-30 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物

Country Status (26)

Country Link
US (7) US9458130B2 (enExample)
EP (2) EP4063357B1 (enExample)
JP (4) JP2018501217A (enExample)
KR (1) KR102620681B1 (enExample)
CN (2) CN111110677A (enExample)
AU (4) AU2015355226B2 (enExample)
BR (1) BR112017011555B1 (enExample)
CA (1) CA2968977A1 (enExample)
CL (2) CL2017001376A1 (enExample)
CO (1) CO2017005498A2 (enExample)
DK (1) DK3227273T3 (enExample)
EA (1) EA201791226A1 (enExample)
ES (2) ES2910528T3 (enExample)
HU (1) HUE058212T2 (enExample)
IL (4) IL301320B2 (enExample)
MX (1) MX385586B (enExample)
MY (1) MY185516A (enExample)
PE (1) PE20171646A1 (enExample)
PH (1) PH12017501007B1 (enExample)
PL (1) PL3227273T3 (enExample)
PT (1) PT3227273T (enExample)
SG (1) SG11201704332YA (enExample)
TW (1) TWI694069B (enExample)
UA (1) UA122780C2 (enExample)
WO (1) WO2016089766A1 (enExample)
ZA (1) ZA201703481B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301320B2 (en) 2014-12-02 2024-11-01 Minerva Neurosciences Inc Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN113694065A (zh) * 2016-05-25 2021-11-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CN107721988A (zh) * 2017-10-31 2018-02-23 无锡福祈制药有限公司 具有抗炎活性的异吲哚‑1‑酮类化合物
EP3840835A1 (en) 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
TWI841545B (zh) * 2018-12-12 2024-05-11 日商田邊三菱製藥股份有限公司 耐胃性控制釋放經口劑型
US12441701B2 (en) * 2019-06-28 2025-10-14 Tapi Czech Industries S.R.O. Solid state forms of roluperidone and salts thereof
IL298323B2 (en) 2020-05-20 2023-10-01 Univ Illinois A method for treating lysosomal storage disease using histatin peptides
CN116251078B (zh) * 2021-12-09 2025-12-19 河北以岭医药研究院有限公司 一种盐酸度洛西汀肠溶胶囊及其制备方法
EP4479049B1 (en) 2022-02-14 2025-12-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms
WO2026035878A1 (en) * 2024-08-07 2026-02-12 Nimbus Saturn, Inc. Hpk1 inhibitor formulations and methods of making the same
WO2026035872A1 (en) * 2024-08-07 2026-02-12 Nimbus Saturn, Inc. Hpk1 inhibitor formulations and methods of making the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1426405A (zh) * 2000-02-29 2003-06-25 三菱制药株式会社 新型环状酰胺衍生物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ATE102482T1 (de) 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
EP0497843A4 (en) 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
FR2797643B1 (fr) 1999-08-17 2003-06-06 Rhodia Chimie Sa Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures
WO2002076432A2 (en) 2001-03-26 2002-10-03 Novartis Ag Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
JP5281395B2 (ja) 2005-06-06 2013-09-04 メルク シャープ エンド ドーム リミテッド 統合失調症の治療用のｇｌｙｔ１阻害剤としてのシクロヘキサンスルホニル誘導体
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
WO2012012542A1 (en) * 2010-07-20 2012-01-26 Cyrenaic Pharmaceuticals, Inc. Methods of use of cyclic amide derivatives to treat schizophrenia
RU2746871C2 (ru) * 2010-07-20 2021-04-21 Сиренейк Фармасьютикалз Инк. Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2012227936A1 (en) * 2011-03-17 2013-10-17 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
IL301320B2 (en) 2014-12-02 2024-11-01 Minerva Neurosciences Inc Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN113694065A (zh) 2016-05-25 2021-11-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
EP3840835A1 (en) 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1426405A (zh) * 2000-02-29 2003-06-25 三菱制药株式会社 新型环状酰胺衍生物

Also Published As

Publication number Publication date
DK3227273T3 (da) 2022-05-02
AU2020204286A1 (en) 2020-07-16
US20170042877A1 (en) 2017-02-16
PH12017501007B1 (en) 2024-07-03
EP4063357B1 (en) 2025-12-31
JP2018501217A (ja) 2018-01-18
US9730920B2 (en) 2017-08-15
IL252347B (en) 2021-01-31
MX385586B (es) 2025-03-18
PH12017501007A1 (en) 2017-12-18
US20210228561A1 (en) 2021-07-29
IL280052B1 (en) 2023-05-01
MX2017007065A (es) 2017-12-18
AU2021229240B2 (en) 2023-08-24
IL313572A (en) 2024-08-01
US20250195494A1 (en) 2025-06-19
PT3227273T (pt) 2022-04-06
EP3227273A1 (en) 2017-10-11
IL301320A (en) 2023-05-01
NZ770365A (en) 2023-10-27
EA201791226A1 (ru) 2017-09-29
IL301320B1 (en) 2024-07-01
PL3227273T3 (pl) 2022-05-30
IL280052A (en) 2021-03-01
ZA201703481B (en) 2023-12-20
TWI694069B (zh) 2020-05-21
AU2015355226A1 (en) 2017-06-08
US10799493B2 (en) 2020-10-13
CO2017005498A2 (es) 2017-09-20
US20200022968A1 (en) 2020-01-23
US9458130B2 (en) 2016-10-04
BR112017011555A2 (pt) 2018-01-09
IL280052B2 (en) 2023-09-01
EP4063357A1 (en) 2022-09-28
WO2016089766A1 (en) 2016-06-09
IL252347A0 (en) 2017-07-31
ES3065087T3 (en) 2026-05-04
BR112017011555B1 (pt) 2023-10-03
US10258614B2 (en) 2019-04-16
AU2020204286B2 (en) 2021-06-17
HUE058212T2 (hu) 2022-07-28
AU2015355226B2 (en) 2020-04-02
MY185516A (en) 2021-05-19
UA122780C2 (uk) 2021-01-06
JP2020172531A (ja) 2020-10-22
CL2017001376A1 (es) 2018-02-16
TW201632511A (zh) 2016-09-16
KR20170106310A (ko) 2017-09-20
AU2021229240A1 (en) 2021-10-07
PE20171646A1 (es) 2017-11-13
CA2968977A1 (en) 2016-06-09
ES2910528T3 (es) 2022-05-12
CN107567444A (zh) 2018-01-09
US20180153871A1 (en) 2018-06-07
KR102620681B1 (ko) 2024-01-04
US20230201184A1 (en) 2023-06-29
AU2023258386A1 (en) 2023-11-23
CL2021000044A1 (es) 2021-06-04
NZ732033A (en) 2023-10-27
JP2022105159A (ja) 2022-07-12
SG11201704332YA (en) 2017-06-29
AU2023258386B2 (en) 2025-10-23
IL301320B2 (en) 2024-11-01
JP7069253B2 (ja) 2022-05-17
JP2025004090A (ja) 2025-01-14
EP3227273B1 (en) 2022-02-09
US20160152597A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
AU2023258386B2 (en) Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
KR20180021693A (ko) 신경퇴행성 질환을 치료하는 조성물 및 방법
CN108883110A (zh) 使用食欲素-2受体拮抗剂治疗抑郁症的方法
JP2025071236A (ja) 代謝機能不全によって引き起こされる腫瘍の治療
BR122023014589B1 (pt) Usos de formulação farmacêutica que compreende di-hidrato de monocloridrato de 2-((1-(2-(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil) isoindolin-1-ona
NZ770365B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
EA040638B1 (ru) Фармацевтический состав, содержащий 2-((1-(2-(4-фторфенил)-2-оксоэтил)пиперидин-4-ил)метил)изоиндолин-1-он для лечения психоневрологического заболевания или расстройства сна, способ лечения психоневрологического заболевания или расстройства сна, таблетка и набор
NZ732033B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination